tbuckley/cabot-search huggingface dataset:
AMA Expanding Drug Information To Physicians
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Received
Journal: British Journal of Dermatology (1989)

British Journal of DermatologyVolume 121, Issue 3 p. 418-418 Book Received First published: September 1989 https://doi.org/10.1111/j.1365-2133.1989.tb01443.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume121, Issue3September 1989Pages 418-418 RelatedInformation
Increasing Risks From Algal Blooms Detected at Freshwater Lakes
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3816: Corilagin could help to overcome PARP inhibitor resistance by inhibiting ERK signaling pathways
Authors: Baoxin Luan, Hongbo Zhao, Robert C. Bast, Zhen Lu, Yinhua Yu
Journal: Cancer Research (2019)

Abstract We have identified that Corilagin is a major anti-tumor active component extracted from a well-known hepatoprotective and antiviral medicinal herb, Phyllanthus niruri L. Our previous work found that Corilagin inhibited the growth of ovarian cancer cells via TGF-β/AKT/ERK signaling pathways. Corilagin also sensitizes Paclitaxel and Carboplatin by primarily inhibiting Snail-glycolysis pathways. Recently, we have investigated if Corilagin could give a help to overcome poly ADP ribose polymerase (PARP) inhibitors (PARPi) resistance in ovarian cancer cells. As we knew, PARP inhibitors are DNA repair drugs, have been approved for ovarian cancer therapy, but drug resistance is a faced problem, combination therapy may give helps. In this study, two pairs of PARPi sensitive/resistant cells: A2780CP/A2780CP_R and UMB1.289/UMB1.289_R (Sci Transl Med. 2017; 9:392) were used. Cells were cloned again and confirmed their sensitivities to PARPi. The IC50 of PARPi-BMN673 is 0.02μM to A2780CP, &amp;gt 10μM to A2780CP_R, 0.12μM to UMB1.289 and 60μM to UMB1.289_R. The combination assays showed Corilagin had almost equally cytotoxic activities to these two pairs and had synergistic effects with BMN673 to A2780CP_R and UMB1.289_R . Using CulcuSyn, the combination indexes (CI) presented at IC50 are 0.17365 and 0.62787 in A2780_R and UMB1.289_R, respectively. Signaling analysis found that PARPi did down-regulate the expression levels of PARP and up-regulate of pH2AX, PARPi only inhibited pERK activity in sensitive cells, but not in resistant cells. In contrast, Corilagin did not have DNA repair function, but it inhibited pERK activity in both sensitive and resistant cells. In summary, we demonstrate that combined treatment with Corilagin and PARPi evokes synergistic cytotoxic effects in two pairs of ovarian cancer cell models. Corilagin is an herb medicine with lower toxic effects to normal cells, especially hepatoprotective, which could be an ideal complimentary medicine when combinating with PARPi in ovarian cancer therapy. Citation Format: Baoxin Luan, Hongbo Zhao, Robert C. Bast, Jr., Zhen Lu, Yinhua Yu. Corilagin could help to overcome PARP inhibitor resistance by inhibiting ERK signaling pathways [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3816.
Abstract SY33-02: Understanding the dynamics of cancer: From developmental pathways to in vivo imaging.
Authors: Tannishtha Reya
Journal: Cancer Research (2013)

Abstract Our research focuses on the signals that control hematopoietic stem cell self-renewal and differentiation, how these signals are utilized during regeneration and how their dysregulation may lead to cancer. Using a multitude of genetic models, we have shown that classic developmental signaling pathways such as Wnt, Hedgehog and Notch play key roles in stem cell growth and regeneration and are dysregulated during leukemia development. In addition, we have used real-time imaging strategies to show that hematopoietic stem cells have the capacity to undergo both symmetric and asymmetric division, and that shifts in the balance between these modes of division are controlled by the microenvironment and subverted by oncogenes. Importantly, we have shown that regulators of this process, including the cell fate determinant Musashi, can promote aggressive cancers and could serve as critical targets for diagnostics and therapy. Most recently, we have developed a high resolution in vivo imaging system that has allowed us to begin to map the behavior and interactions of hematopoietic stem cells with the microenvironment within living animals, and to define how these change during regeneration and cancer formation. Citation Format: Tannishtha Reya. Understanding the dynamics of cancer: From developmental pathways to in vivo imaging. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr SY33-02. doi:10.1158/1538-7445.AM2013-SY33-02
Études radiologiques sur le poumon et le médiastin.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEF2A sequence variants and coronary artery disease: a change of heart?
Authors: D. Altshuler
Journal: Journal of Clinical Investigation (2005)

Rare mutations in MEF2A have been proposed as a cause of coronary artery disease (CAD) and myocardial infarction (MI). In this issue of the JCI, Pennacchio and colleagues report sequencing MEF2A in 300 patients with premature CAD and in controls. Only 1 CAD patient was found to carry a missense mutation not found in controls. The specific 21-bp deletion in MEF2A previously proposed as causal for CAD and/or MI was observed in unaffected individuals and did not segregate with CAD in families. These results do not support the hypothesis that mutations in MEF2A are a cause of CAD and/or MI but do illustrate general principles regarding the difficulty of connecting genetic variation to common diseases.
Allergic contact dermatitis from carbonless copy paper
Authors: J. G. Marks
Journal: JAMA (1981)

PAPERMAKING, as the Chinese developed it almost 2,000 years ago, was a simple process using natural ingredients. The basic procedure involved breaking up raw materials such as straw, leaves, and rags into cellulose fibers. These fibers were suspended in water and formed into felted sheets with a filtering device. The modern paper-pulp industry has modified the basic process with various chemicals to refine and alter the wood pulp. It is a highly technical science requiring both natural and synthetic materials. The composition of the final product varies depending on the intended use, whether it be for writing, printing, wrapping, filtering, or cleaning. In this report, allergic contact dermatitis to a new paper product, carbonless copy paper, is documented. <h3>Report of a Case</h3> A 21-year-old woman had a 1 1/2-year history of an intermittent eruption of the face and neck (Fig 1). She worked as a clerk in a college registrar's
Risk factors for underimmunization in poor urban infants
Authors: A. S. Bates
Journal: JAMA (1994)

<h3>Objective.</h3> —To assess risk factors for underimmunization in poor urban infants. <h3>Design.</h3> —Prospective cohort study. <h3>Setting.</h3> —A large municipal teaching hospital in the Midwest. <h3>Participants.</h3> —A total of 464 healthy, full-term newborn infants delivered at a large municipal teaching hospital who were to be discharged to the care of their mothers. Mothers were interviewed 24 to 72 hours post partum regarding personal and financial characteristics and 9 to 12 months later to determine where immunizations had been received. <h3>Main Outcome Measures.</h3> —Immunization status at 3 and 7 months of age. <h3>Results.</h3> —Despite availability of free vaccine to most patients, only 67% had received their first set of immunizations by 3 months of age, and only 29% were up-to-date by 7 months of age. Marital status, coresidence with the infant's grandmother, adequacy of prenatal care, and perceived barriers to care were significant independent predictors of initiation of immunizations by 3 months and completion of immunization by 7 months. Poverty was also an independent predictor of immunization status at 7 months. Perceived susceptibility to common symptoms and perceived benefit of medical care to prevent disease were inversely related to immunization status at 7 months. <h3>Conclusions.</h3> — These data suggest that poor urban infants of single mothers and of mothers who received inadequate prenatal care, and those not living with their grandmother should be targeted for tracking and follow-up to ensure adequate immunization. The provision of free vaccine alone will not guarantee adequate immunization coverage of poor urban children. (<i>JAMA</i>. 1994;272:1105-1110)
Abstract 23083: Glycemic Therapies, Atherothrombotic And Heart Failure Risk, And Outcomes By Baseline Cardiovascular Disease Status: Meta-analysis of Large CV Outcome Trials
Authors: Jacob A Udell
Journal: Circulation (2017)

Purpose/Background: Recent glycemic therapy CV outcome trials have demonstrated risk reduction on the composite of CV death, MI or stroke (atherothrombotic MACE) and heart failure (HF). We investigated whether effects are modified by weight change, an indirect marker of intravascular volume status and explored among effective therapies heterogeneity by baseline CVD status. Methods: Random-effects metaanalysis among glycemic therapy CV outcome trials on the relative risk (RR) of MACE and HF. Results: Among 21 trials of 149,916 patients, 5,749 (3.8%) HF and 15,357 (10.2%) MACE events occurred during a mean 3.9 years of follow-up (range 1.5-10 years). Across classes of glycemic therapy there was substantial heterogeneity for the risk of HF (I 2 =74%; P-interaction &lt;0.0001) but not MACE (I 2 =31%; P-interaction=0.08). Among effective therapies, reduction in MACE risk was confined to patients with established CVD (HR 0.82, 95% CI, 0.77-0.89) with no effect among patients without CVD (HR 1.06, 95% CI, 0.86-1.31; P-interaction=0.02; Figure). Meta-regression showed that every 1 kg change in weight between therapies modified the RR for HF by 4.8% (95% CI 2.5-7.0; P=0.00002). Conclusion: An effect on MACE appears confined to secondary prevention whereas an effect on HF appears related to achieved weight change between glycemic therapies.
Thiazide-induced immune hemolytic anemia
Authors: J. M. Vila
Journal: JAMA (1976)

SINCE the first report of drug-induced hemolytic anemia produced by stibophen,<sup>1</sup>the list has been expanded to include 16 other drugs and chemical compounds.<sup>2</sup> This group of hemolytic anemias has been classified as "immune" because to become antigenic the drug must combine with a macromolecule in the serum, thus forming a drug-antidrug complex.<sup>3</sup>This complex attaches to the red blood cell (RBC) membrane by an unknown mechanism and leads to RBC destruction either by activation of complement or by binding of active C3 to the RBC surface, with subsequent recognition by the macrophages and destruction in the reticuloendothelial system.<sup>4</sup> Several drugs have been reported to produce hemolysis without binding complement.<sup>5-7</sup>In these cases, RBC destruction is probably due to coating of RBCs by immunoglobulins. In the present case, an oral antihypertensive drug that is a combination of methyldopa and hydrochlorothiazide (Aldoril) produced immune hemolytic anemia
Error in Figure 3
Authors: Karlo Lizarraga, Philip Thompson, Anthony Lang, Edmond Safra, Gloria Shulman
Journal: JAMA Neurology (2019)

Bernard J. Hanseeuw, MD; Rebecca A. Betensky, PhD; Heidi I. L. Jacobs, PhD; Aaron P. Schultz, PhD; Jorge Sepulcre, MD; J. Alex Becker, PhD; Danielle M. Orozco Cosio, BS; Michelle Farrell, PhD; Yakeel T. Quiroz, PhD; Elizabeth C. Mormino, PhD; Rachel F. Buckley, PhD; Kathryn V. Papp, PhD; Rebecca A. Amariglio, PhD; Ilse Dewachter, PhD; Adrian Ivanoiu, MD; Willem Huijbers, PhD; Trey Hedden, PhD; Gad A. Marshall, MD; Jasmeer P. Chhatwal, MD; Dorene M. Rentz, PsyD; Reisa A. Sperling, MD; Keith Johnson, MD
Wound Ballistics
Authors: Basil A. Pruitt
Journal: JAMA (1988)

<h3>To the Editor. —</h3> In his recent review, Dr Fackler<sup>1</sup>suggests that current treatment of missile wounds is inappropriate as a result of what he terms misconceptions, half-truths, and misinterpretation of wound ballistics studies. As beauty is in the eye of the beholder, misinterpretation appears to be in the mind of the reader, since it would be difficult for most to interpret the recommendations of the various authors cited as favoring débridement of excessive amounts of viable tissue.<sup>2,3</sup>Dr Fackler appears to confuse the results of laboratory studies with clinical practice. Experienced surgeons do not débride cavities of any sort—they excise tissue that appears to be dead and preserve viable tissue. In the absence of specific data, Dr Fackler suggests that the lower incidence of clostridial myositis in conflicts since World War I correlates with increased antibiotic use, but it also correlates with increased understanding of wound ballistics,
Contents
Authors: R Finn, L Amiot, N Vu, M Rauch, A L'helgoualc'h, F Chalmel, H Gascan, B Turlin, D Guyader, M Samson, M.-L Yu, C.-Y Dai, C.-F Huang, J.-J Lee, M.-L Yeh, S.-M Yeh, H.-T Kuo, J.-F Huang, J.-M Chang, H.-C Chen, S.-H Juo, S.-J Hwang, W.-L Chuang, K Kielland, G Delaveris, S Rogde, T Eide, E Amundsen, O Dalgard, T Gustot, E Maillart, M Bocci, R Surin, E Tre ´po, D Degre, V Lucidi, F Taccone, M.-L Delforge, J.-L Vincent, V Donckier, F Jacobs, C Moreno, J Cordoba, M Ventura-Cots, M Simo ´n-Talero, A Amoro, M Pavesi, H Vilstrup, P Angeli, M Domenicali, P Gine, M Bernardi, V Arroyo
Journal: Journal of Hepatology (2014)
Early Cellular Effects of Circulating Cadmium-Thionein on Kidney Proximal Tubules
Authors: Katherine S. Squibb, James W. Ridlington, Neil G. Carmichael, Bruce A. Fowler
Journal: Environmental Health Perspectives (1979)

Circulating cadmium-thionein (Cd-MT) is cleared from the mammalian circulatory system by filtration through the kidney glomerulus with subsequent reabsorption by kidney proximal tubules. Damage to the tubules results following uptake of Cd-MT, which is dependent upon time and the dose level of cadmium administered. Intravenous administration of 109Cd-MT at doses of 0.017 and 0.17 mg Cd/kg body weight with examination of total renal uptake of 109Cd at 0.5, 3, and 24 hr disclosed that the rate of clearance from the blood and uptake by the kidney was significantly more rapid at the 0.017 mg Cd/kg dose. Ultrastructural changes resulting from intravenous injection of either form A or B of Cd-MT were characterized by increased numbers of pinocytotic vesicles and small, dense lysosomal structures. There was no evidence of mitochondrial swelling or cell death at either 3 or 6 hr after injection. The subcellular distribution of cadmium in kidney tissue at various times after administration of Cd-MT was determined by using differential centrifugation techniques with 109Cd and in situ by using x-ray microanalysis. At 30 min after injection of Cd-MT, significant amounts of cadmium were present in lysosomal fractions indicating an interaction between the tubular lysosome system and Cd-MT prior to the onset of overt cellular toxicity. Results suggest that Cd-MT is reabsorbed and broken down by kidney tubule cells in a physiological manner with possible subsequent release of the toxic cadmium ion.
Numerical Error.
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).
Authors: Andreas Schneeweiss, Volker Moebus, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, Claus Hanusch, Joern Hilfrich, Jens Bodo Huober, Christian Jackisch, Stefan Paepke, Sherko Kümmel, Hans Tesch, Michael Untch, Sibylle Loibl, Gunter Von Minckwitz
Journal: Journal of Clinical Oncology (2015)

TPS1101 Background: The sequential use of dose-dense, dose-intensified epirubicin, paclitaxel, and cyclophosphamide (EPC) (Möbus et al. J Clin Oncol 2010) as well as weekly treatment with paclitaxel/liposomal doxorubicin (plus carboplatin in triple negative disease, TNBC) (PM(Cb)) (von Minckwitz et al. Lancet Oncol 2014), both with dual HER2 blockade in HER2+ breast cancer (BC), are considered highly efficient regimens for high-risk early stage BC patients and will be compared in the GeparOcto study. Methods: GeparOcto (NCT02125344) will randomize patients to 18 weeks EPC (E 150mg/m² q2w for 3 cycles, P 225mg/m² q2w for 3 cycles, C 2000mg/m² q2w for 3 cycles) or PM(Cb) (P 80mg/m² q1w concomitantly with M 20mg/m² q1w and, in case of TNBC, Cb AUC 1.5 q1w). Patients with HER2+ BC will receive trastuzumab 6 (8) mg/kg q3w and pertuzumab 420 (840) mg q3w concomitantly with all P, C, and PM(Cb) cycles. Patients with untreated, histologically confirmed, cT1c - cT4a-d BC and central receptor assessment can be included. Patients with HER2+ or TNBC are eligible irrespective of nodal status, luminal B-like tumors only if pN+. Primary objective is to compare pCR rates (ypT0/is ypN0). Sample size calculations assumed a pCR rate of 50% for EPC and 60% for PM(Cb), requiring 950 patients to show superiority of PM(Cb). Secondary objectives are to compare pCR rates between treatment arms within the stratified subpopulations (BC subtype [HER2+ HR+/- vs HER2- HR+ vs HER2- HR-], Ki-67 [ ≤ 20 vs > 20%], lymphocyte-predominant BC [no vs yes]), amongst others. Due to a high risk of chemotherapy induced anemia in both regimens, patients are also randomized to parenteral ferric carboxymaltose or physician's choice for treatment of iron deficient patients. Results: Recruitment started in 12/2014 and is planned for 18 months at 80-100 sites in Germany. 65 patients were recruited by 1st Feb 2015. Conclusions: GeparOcto investigates the efficacy of dose-dense dose-intensified EPC compared to weekly PM(Cb), both with dual HER2-blockade in HER2+ BC, in high-risk early stage patients and compares anemia management strategies. Clinical trial information: NCT02125344.